이경민 임상조교수대우
#폐암 #유방암
|
학력
2007 .03 ~ 2013 .02 : 고려대학교 의과대학 의학사
2016 .03 ~ 2018 .02 : 울산대학교 의과대학 의학석사
2016 .03 ~ 2018 .02 : 울산대학교 의과대학 의학석사
경력
2018 .03 ~ 2019 .08 : 서울아산병원 종양내과 임상강사
2019 .09 ~ 2020 .02 : 고대구로병원 혈액종양내과 임상강사
2020 .03 ~ : 고대구로병원 혈액종양내과 임상조교수대우
2019 .09 ~ 2020 .02 : 고대구로병원 혈액종양내과 임상강사
2020 .03 ~ : 고대구로병원 혈액종양내과 임상조교수대우
논문
[SCI] (The clinical outcomes of rituximab biosimilar CT-P10 (Truxima((R))) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experience.)
[SCI] (The clinical outcomes of undifferentiated pleomorphic sarcoma (UPS): A single-centre experience of two decades with the assessment of PD-L1 expressions)
[SCI] (Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.)
[SCI] (Feasibility, safety, and adequacy of research biopsies for cancer clinical trials at an academic medical center.)
[SCI] (Systemic HD-MTX for CNS prophylaxis in high-risk DLBCL patients: a prospectively collected, single-center cohort analysis)
[SCI] (Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing.)
[SCI] (The clinical outcomes of undifferentiated pleomorphic sarcoma (UPS): A single-centre experience of two decades with the assessment of PD-L1 expressions)
[SCI] (Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.)
[SCI] (Feasibility, safety, and adequacy of research biopsies for cancer clinical trials at an academic medical center.)
[SCI] (Systemic HD-MTX for CNS prophylaxis in high-risk DLBCL patients: a prospectively collected, single-center cohort analysis)
[SCI] (Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing.)
저서
저서 내용이 없습니다.
보도자료
보도자료 내용이 없습니다.
포스팅
포스팅 내용이 없습니다.
영상자료
영상자료 내용이 없습니다.
발표자료
발표자료 내용이 없습니다.